Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TBD-TL1A
- Development stage
- Preclinical
- Lead developer
- OroGen BioSciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TBD-TL1A is a preclinical-stage small molecule inhibitor of tumor necrosis factor-like ligand 1A (TL1A), being developed by Orogen Therapeutics for the treatment of inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD). TL1A is a key cytokine involved in mucosal inflammation and tissue fibrosis. By targeting TL1A, TBD-TL1A aims to inhibit downstream inflammatory pathways and prevent fibrotic remodeling in the gut, offering a potential oral small-molecule alternative to existing biologic therapies.
- Other names
- TBD
02
Targets
DR3 (Tumor necrosis factor receptor superfamily member 25)TL1A (TNF-like cytokine 1A)
Beyond the preview
Go deeper on TBD-TL1A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TBD-TL1A.